J&J Remicade Sales Aid Cited By FDA For “Misleading” Efficacy Claims
Executive Summary
A Remicade sales aid contains unsubstantiated effectiveness claims and omits risk information, the Center for Drug Evaluation & Research's advertising division says in a Feb. 11 "untitled" letter to Johnson & Johnson's Centocor division
You may also be interested in...
Enbrel TV Ad Highlighting “Breakthrough Therapy” Draws FDA Warning Letter
A television commercial for Amgen's Enbrel (etanercept) describing the TNF inhibitor as a "breakthrough" psoriasis therapy has drawn an FDA warning letter
Enbrel TV Ad Highlighting “Breakthrough Therapy” Draws FDA Warning Letter
A television commercial for Amgen's Enbrel (etanercept) describing the TNF inhibitor as a "breakthrough" psoriasis therapy has drawn an FDA warning letter
J&J Is Spitzer’s Next Target: New York AG Opens Broad Off-Label Investigation
Johnson & Johnson is responding to a request from the New York Attorney General for information about marketing practices for its six largest prescription drug brands